2,4 Dinitrophenol as Medicine.

Area of Science:

• Biochemistry
• Neuroscience
• Pharmacology

Background:

• Historically, drug discovery has overlooked targeting the energy-out aspect of cellular metabolism, specifically mitochondrial energy expenditure.
• Mitochondrial uncouplers, like 2,4-dinitrophenol (DNP), were used for weight loss in the 1930s but lacked mechanistic understanding and FDA approval.
• Neurodegenerative diseases are increasingly linked to mitochondrial dysfunction, oxidative stress, and reactive oxygen species (ROS) production.

Purpose of the Study:

• To explore the repositioning of DNP as a disease-modifying therapeutic for various insidious illnesses, unrelated to weight reduction.
• To investigate DNP's potential in treating 'metabesity' and neurodegenerative disorders by targeting mitochondrial physiology.
• To assess DNP's novel effects, including the induction of neurotrophic growth factors.

Main Methods:

• Review of historical data on DNP usage and its physiological effects.
• Analysis of the role of mitochondrial dysfunction and ROS in neurodegenerative diseases.
• Focus on DNP's application at low, weight-neutral doses.
• Mention of the FDA granting Investigational New Drug (IND) approval for DNP clinical testing.

Main Results:

• Mitochondrial uncouplers like DNP can lower ROS production and calcium overload, implicated in neurodegeneration.
• Evidence suggests elevated isoprostanes (a marker of mitochondrial ROS) precede Alzheimer's Disease onset.
• DNP has demonstrated induction of neurotrophic growth factors crucial for neuronal health and cognition.

Conclusions:

• DNP, at low doses, presents a potential disease-modifying strategy for neurodegenerative conditions and 'metabesity'.
• Managing ROS production through DNP could potentially delay or prevent age-related disease onset.
• Phase I clinical trials are initiated to rigorously evaluate DNP's safety, tolerability, and pharmacokinetics in humans.